Abstract
Simple SummaryEpigenetic modifications can regulate gene expression by altering chromatin structure. Since the beginning of comprehensive research into changes in gene expression due to early DNA methylation and histone acetylation, numerous experimental studies have revealed that the regulation of gene expression by histone methyltransferases plays an important role in cancer development, metastasis, and drug resistance. The enzyme responsible for H3K4 methylation, which is highly correlated with active transcription, has been studied in detail via impaired regulation of gene expression, following rearrangement of the mixed-lineage leukemia 1 (MLL1) gene. Other H3K4 methyltransferases have also been identified and have been shown to play a role in various cancers. In this review, we have examined the overall role of histone H3K4 methyltransferase in the development and progression of various cancers and its specific role in the development of drug-resistant cancers commonly encountered during chemotherapy. Additionally, we have discussed the H3K4-specific methyltransferase inhibitors currently under development for cancer treatment as well as their mechanisms of action.The KMT2 (MLL) family of proteins, including the major histone H3K4 methyltransferase found in mammals, exists as large complexes with common subunit proteins and exhibits enzymatic activity. SMYD, another H3K4 methyltransferase, and SET7/9 proteins catalyze the methylation of several non-histone targets, in addition to histone H3K4 residues. Despite these structural and functional commonalities, H3K4 methyltransferase proteins have specificity for their target genes and play a role in the development of various cancers as well as in drug resistance. In this review, we examine the overall role of histone H3K4 methyltransferase in the development of various cancers and in the progression of drug resistance. Compounds that inhibit protein–protein interactions between KMT2 family proteins and their common subunits or the activity of SMYD and SET7/9 are continuously being developed for the treatment of acute leukemia, triple-negative breast cancer, and castration-resistant prostate cancer. These H3K4 methyltransferase inhibitors, either alone or in combination with other drugs, are expected to play a role in overcoming drug resistance in leukemia and various solid cancers.
Highlights
Epigenetics refers to heritable alterations in gene expression that are not caused by changes in the DNA sequence [1]
We examine the overall role of histone H3K4-specific methyltransferase in cancer and explore the role of histone methyltransferases (HMTs) in drug-resistant cancers
Binding to WD-repeat protein 5 (WDR5) via a conserved arginine-containing WDR5 interaction (Win) motif located at the N-terminus of the SET domain of the mixed-lineage leukemia (MLL) family is essential for the assembly and enzymatic activity of the MLL core complex [37,38]
Summary
Epigenetics refers to heritable alterations in gene expression that are not caused by changes in the DNA sequence [1]. Epigenetic studies focused on changes in gene expression resulting from DNA methylation and histone acetylation. Binding of DOT1L (KMT4) or the super elongation complex (SEC) occurs via a fusion partner (AF4, AF9, AF10, ELL, or ENL) newly bound to the N-terminus of the MLL1 protein, resulting in the introduction of the H3K79me mark at the specific site in the target gene (e.g., HOXA9 or MEIS1) [33]. Binding to WDR5 via a conserved arginine-containing WDR5 interaction (Win) motif located at the N-terminus of the SET domain of the MLL family is essential for the assembly and enzymatic activity of the MLL core complex [37,38]. Additional biochemical experiments have shown that the stable heterodimer formed by ASH2L and RbBP5 promotes the interaction between the SET domain and the substrate, thereby indicating increased overall methyltransferase activity of the KMT2 protein complex which is attributable to the interaction [39]. The split-SET (N-SET and C-SET) domains and the MYND domains located between them form their characteristic active enzyme
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
